Terry has been working in the biotech tools sector for more than 30 years. Prior to joining Astrea, Terry was most recently CEO of Cambridge based Horizon Discovery PLC, a public company listed on the UK AIM market. He was at Horizon for 4 years prior to it being acquired by Perkin Elmer Corp and has spent the last 6 months ensuring a smooth integration of the business into its new home. Previous roles were VP Global Sales for Pacific Biosciences and lead commercial positions at Genetix PLC, aquired by Danaher Corp., and at the Swedish Biotech company Biacore, acquired by GE. Terry started his career in this sector at Applied Biosystems in 1988 in a regional sales role and rose to VP Europe by 2003. Terry graduated with a degree in Physiology and Biochemistry from reading University.
Dr. Steve Burton has over 32 years of experience in company management, business development and the development of separation products and processes for the purification of biopharmaceuticals. He has been instrumental in the development of Astrea’s purification products and technologies which are used extensively for commercial manufacture of recombinant and plasma-derived protein therapeutics. Under Dr Burton’s direction, Astrea Bioseparations has grown to become a leading company in its field with a reputation for innovative, high quality/high performance chromatography adsorbents.
Dr. Burton gained his Ph.D. at the University of Cambridge and worked for Delta Biotechnology (now Albumedix) in the UK before joining Astrea Bioseparations in 1988 as Research and Development Manager.
David is an experienced Chief Financial Officer who has worked in the Astrea Group in various roles since 2007. David joined the Company as UK Financial Controller after obtaining a Bachelor’s degree in Business Studies from the University of Nottingham and then going on to qualify with the Institute of Chartered Accountants in England and Wales within practice, gaining vital commercial and technical experience within multiple sectors. He then progressed to be Group Director of Financial Planning & Analysis, and Finance Director before moving into his current role in early 2020 as Chief Financial Officer.
David heads up the finance team in the UK, whilst working closely with the management team members to provide a wealth of commercial and strategic insight and direction.
Gabe leads global commercial operations and business responsibilities across North America, UK, Europe, and Asia. He also oversees expansion of Astrea’s growing product line in emerging markets. Gabe brings more than 25 years of commercial experience in life sciences and biotherapeutics, developing high performance sales & marketing teams and establishing commercial excellence programs to accelerate profitability and growth; all while championing the customer experience.
Most recently Gabe built a Global Commercial team at Horizon Discovery, leading customer-facing operations and strategy, and establishing a performance-driven Key Account program resulting in over 50% YOY revenue growth. Prior to Horizon, he held several senior roles focused on commercial acceleration and sales success at Danaher Corporation operating companies Molecular Devices LLC, Leica BioSystems and Genetix Ltd. He also previously held multiple sales, marketing, and product management roles with Ventana Medical Systems Inc., a member of the Roche Group.
Marc Hummersone has over 20 years of project and managerial experience in both big and small technology companies, including industry leaders AstraZeneca, General Electric Healthcare & Cytiva. He has a broad experience base across a wide range of technologies including the development of novel chromatographic media for the purification of complex biological feed streams as well as drug discovery and development. He was a key contributor to the development of the Fibro chromatography family of products which resulted in the acquisition of Puridify, by GE Healthcare in 2017. Additionally, he was a key part of the management team who validated the concept of synthetic lethality and who identified and developed Lymparza, which is an approved drug for the treatment of BRCA-mutated advanced ovarian cancer which resulted in the acquisition of KuDOS Pharmaceuticals in 2005, by AstraZeneca. Marc has held positions including Company Director, Chief Scientific Officer and Department Director. He gained a PhD and Post-Doctoral experience in chemistry which was focused on the total synthesis of complex natural products at University College, London.
Colin has over 20 years management experience in Quality and Regulatory Affairs within the Pharmaceutical and Biotech sector. Having begun his career within Quality Control in GSK he moved into other areas of compliance including Herbal, Small Molecule, ATMP and Human Tissue implementing and maintaining HTA and GMP licences in a number of sites using a ISO 9001 Quality Management System and associated certifications.
Colin joined Astrea Bioseparations in 2015 to implement and develop a Quality Management System that adheres to GMP for Active Substances, is compliant with ISO 9001:2015 and uses a Lean approach to manufacturing.
Chris is an Experienced production manager with over 27 years’ experience in chemical and pharmaceutical manufacturing. Having started his career working in a research and development laboratory, Chris progressed into large scale manufacturing of fine chemicals and then into Pharmaceutical API manufacturing with Pfizer. He has a degree in Applied chemistry and is a Chartered Manager.
Chris has been with Astrea Bioseparations (Astrea) for over 6 years with responsibilities covering the manufacturing of mimetic adsorbents. Since joining Astrea, Chris has been instrumental in developing a 5-fold increase in manufacturing capacity to meet Astrea’s ambitious growth expectations.